Transcriptomic Quantitation of Hepatitis B Virus Surface Antigen from Integration
通过整合对乙型肝炎病毒表面抗原进行转录组定量
基本信息
- 批准号:10724716
- 负责人:
- 金额:$ 7.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-05-11 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAntigensBiologicalBlood specimenCharacteristicsChronic Hepatitis BCircular DNACirculationClinicalClinical TrialsCohort StudiesConfidence IntervalsDNADataData AnalysesDigestionExclusionFamilyGenetic TranscriptionHepatitis BHepatitis B InfectionHepatitis B VirusHepatitis B e AntigensHepatocarcinogenesisHepatologyHumanHuman GenomeImmuneImmunosuppressionIncidenceInterruptionKnowledgeLegal patentLiverMeasurementMeasuresMethodsNorth AmericaNuclearOutcomePathogenesisPatientsPersonsPhenotypePreparationPrimary carcinoma of the liver cellsProceduresProteinsQuantitative Reverse Transcriptase PCRResearchResistanceSamplingSerumSourceSpecimenStudy of serumSurface AntigensTissue SampleTissuesTranscriptTransgenic ModelTranslational ResearchUnited States National Institutes of HealthValidationViralViral GenomeVirus Integrationcohortdeoxyguanosine triphosphatedigitalexperimental studyinsightmembernext generation sequencingnovelpromoterreference genomesimulationtranscriptomicsvalidation studiesviral DNAviral RNA
项目摘要
Project Summary
Hepatitis B virus (HBV) surface antigen (HBsAg) is a hallmark in patients with chronic HBV infection (CHB).
Given its close association with clinical outcomes in CHB patients, HBsAg seroclearance is required in
achieving an HBV functional or complete cure. Toward this direction, a major barrier is relevant to its biological
sources. Besides a nuclear reservoir of covalently closed circular DNA (cccDNA), HBsAg could also be
produced from cellular integration. Currently, the contribution of HBV integration to HBsAg remains elusive
due to the lack of a method for quantitative measurement. Transcription from integrated HBV DNA has several
characteristics, such as the retention of human sequences, an early termination, and the interruption of HBV
Core antigen. These features have been used to infer the relative abundance of integration-derived HBsAg
transcripts by qRT-PCR, digital droplet PCR (ddPCR), and next-generation sequencing (NGS). However,
these approaches require liver tissue and have limited use with blood samples from which ~50% of HBeAg-
negative patients have total HBV RNA below the lower limit of quantification of qRT-PCR. Bait-based target
enrichment in NGS could enhance the sensitivity but extensive microhomology between HBV and human
genomes lowers the efficiency. To address these issues, we have developed a novel method through multiple
technical advances from our lab, including template-dependent multiple displacement amplification (tdMDA)
(BioTechniques 2017), a novel target enrichment strategy via 7‑deaza‑dGTP‑resistant enzymatic digestion
(TEED) (BMC Res Notes 2020, patented), and a read simulation to evaluate relative abundance among
reference genomes (J Virol Methods 2022). The combination of tdMDA, TEED, and the read simulation,
termed MATESim, was applied to five CHB patient serum samples. Integration-derived transcripts accounted
for variable portions of total HBsAg transcripts, ranging from 1.8% to 94.3%. These results support the
hypothesis that MATESim would be a noninvasive method to quantitate HBsAg from integration at the level of
transcription. This hypothesis will be evaluated using patient specimens from the Hepatitis B Research
Network (HBRN). First, we will validate MATESim by studying paired serum/liver samples. HBsAg transcripts
from cccDNA and integrated HBV DNA may have different mechanisms for release to circulation. It is
unknown whether their relative abundance determined by MATESim in circulation is a recapitulation, an
underestimation, or an overestimation of liver data. This knowledge will help to interpret data from circulation
by MATESim. Second, we will study serum samples from 59 patients with defined HBV phenotypes in the
HBRN cohort. The experiment will allow us to gain insights into the magnitude and between-patient variance
of integration-derived HBsAg in this patient cohort at a 95% confidence interval. Taken together, as a non-
invasive method to quantitate integration-derived HBsAg, MATESim would be a turning point in translational
research, clinical trials, and patient management for the globally 257 million people infected with HBV.
项目摘要
乙肝病毒表面抗原(HBs-Ag)是慢性乙肝患者的标志物。
由于它与慢性乙肝患者的临床转归密切相关,因此在以下情况下需要进行乙肝表面抗原血清清除
实现乙肝的功能性或完全治愈。朝着这个方向,一个主要的障碍是与其生物学相关的
消息来源。除了共价闭合环状DNA(CccDNA)的核心储存库外,乙肝表面抗原也可能是
从细胞整合中产生。目前,乙肝病毒整合对乙肝表面抗原的贡献仍然难以捉摸。
由于缺乏一种定量测量的方法。从整合的HBVDNA转录有几个
特征,如保留人类序列,提前终止,以及阻断乙肝病毒
核心抗原。这些特征已被用来推断整合衍生的乙肝表面抗原的相对丰度
通过qRT-PCR、数字液滴聚合酶链式反应(DdPCR)和下一代测序(NGS)获得转录本。然而,
这些方法需要肝组织,对血液样本的使用有限,从血液样本中约50%的HBeAg-
阴性患者的总HBVRNA低于qRT-PCR定量下限。诱饵目标
在NGS中的浓缩可以提高乙肝病毒和人类之间的敏感性,但具有广泛的微同源性
基因组降低了效率。为了解决这些问题,我们开发了一种新的方法,通过多次
我们实验室的技术进步,包括模板依赖的多重置换扩增(TdMDA)
(BioTechniques 2017),一种新的通过7-去氮杂-dGTP抗性酶消化的靶向浓缩策略
(Ted)(BMC RES Notes 2020,专利),以及评估以下对象相对丰度的读取模拟
参考基因组(J Virol方法2022)。TdMDA、TED和读取模拟的组合,
对5例CHB患者血清标本进行了MATESim检测。整合衍生的成绩单被计算在内
对于总转录本中的可变部分,从1.8%到94.3%不等。这些结果支持
假设MATESim将是一种从整合水平上定量HBs Ag的非侵入性方法
抄写。这一假设将使用来自乙肝研究的患者样本进行评估。
网络(HBRN)。首先,我们将通过研究配对的血清/肝脏样本来验证MATESim。乙肝病毒表面抗原转录本
CccDNA和整合的HBVDNA可能有不同的释放到循环的机制。它是
尚不清楚由循环中的MATESim确定的它们的相对丰度是否是一种概括,以及
低估或高估肝脏数据。这一知识将有助于解释来自流通的数据
由MATESim提供。其次,我们将研究59名明确乙肝病毒表型的患者的血清样本。
HBRN队列。这项实验将使我们能够深入了解患者之间的差异和大小
整合衍生的乙肝表面抗原在该患者队列中的可信区间为95%。总而言之,作为一个非
侵入性方法定量整合衍生的乙肝表面抗原,MATESim将是翻译的一个转折点
为全球2.57亿感染乙肝病毒的人提供研究、临床试验和患者管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAOFENG FAN其他文献
XIAOFENG FAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAOFENG FAN', 18)}}的其他基金
A Novel Human Virus in Patients with Cryptogenic Liver Disease
隐源性肝病患者中的一种新型人类病毒
- 批准号:
10636331 - 财政年份:2023
- 资助金额:
$ 7.58万 - 项目类别:
A High throughput Reverse Genetics System for Hepatitis C Virus
丙型肝炎病毒的高通量反向遗传学系统
- 批准号:
8891839 - 财政年份:2015
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
7570083 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
8037137 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
8242874 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
丙型肝炎病毒准种对抗病毒治疗的耐药性
- 批准号:
7774317 - 财政年份:2008
- 资助金额:
$ 7.58万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Effects of cancer-testis antigens on the signaling and biological activity of the malignant melanoma cells
癌睾丸抗原对恶性黑色素瘤细胞信号传导和生物活性的影响
- 批准号:
26860894 - 财政年份:2014
- 资助金额:
$ 7.58万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Molecular biological research for Periodontal pathogenic surface antigens of Campylobacter rectus.
直肠弯曲杆菌牙周病原表面抗原的分子生物学研究。
- 批准号:
13671913 - 财政年份:2001
- 资助金额:
$ 7.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Chlamydia pneumoniae Antigens of Biological Significance
具有生物学意义的肺炎衣原体抗原
- 批准号:
7026454 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:
CHLAMYDIA PNEUMONIAE ANTIGENS OF BIOLOGICAL SIGNIFICANCE
具有生物学意义的肺炎衣原体抗原
- 批准号:
2637348 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:
CHLAMYDIA PNEUMONIAE ANTIGENS OF BIOLOGICAL SIGNIFICANCE
具有生物学意义的肺炎衣原体抗原
- 批准号:
2887732 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:
Elucidation for biological significance of cancer-associated carbohydrate antigens through genetic modification of carbohydrates
通过碳水化合物的基因修饰阐明癌症相关碳水化合物抗原的生物学意义
- 批准号:
10671215 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Chlamydia pneumoniae Antigens of Biological Significance
具有生物学意义的肺炎衣原体抗原
- 批准号:
6877105 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:
Chlamydia pneumoniae Antigens of Biological Significance
具有生物学意义的肺炎衣原体抗原
- 批准号:
6624069 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:
Chlamydia pneumoniae Antigens of Biological Significance
具有生物学意义的肺炎衣原体抗原
- 批准号:
6472104 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:
CHLAMYDIA PNEUMONIAE ANTIGENS OF BIOLOGICAL SIGNIFICANCE
具有生物学意义的肺炎衣原体抗原
- 批准号:
6170907 - 财政年份:1998
- 资助金额:
$ 7.58万 - 项目类别:














{{item.name}}会员




